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1. Introduction 
1.1 Toxicity assays 
For most of their lives, humans are exposed to a variety of chemicals from different sources. 
The characterization of chemicals’ toxicity implies the necessity to have available reliable 
testing methods to assess their capability to produce adverse effects on living organisms. 
Thus, it is necessary to acquire a battery of relevant internationally agreed methods to be 
employed by governments, industry and independent laboratories to assess the safety of 
chemicals. Presently, a set of validated tests is widely used to analyze the toxicity of 
chemicals and pharmaceutical drugs and to ensure their safety, and is recognized for this 
purpose (OECD, 2008; Stummann et al., 2009). 
OECD Guidelines require in vivo studies to comply with the human health risk assessment 
process before registering and authorizing the use of chemicals. Toxicity guidelines 
characterize the adverse effects against the target organism that are attributable to exposure 
to the tested chemical with two main purposes in mind: the hazard identification and risk 
assessment deriving from exposure to the assessed chemical (Estevan et al., 2011). 
Currently, the OECD has at least one in vivo validated guideline for testing the following 
endpoints: skin sensitization, skin and eye irritation and corrosion, mutagenicity, acute 
toxicity, target organ systemic toxicity (repeated daily dose for 28 days, 90 days, and for 
more than 12 months), carcinogenicity and toxicity to reproduction (screening, 
teratogenicity and two generations). All these OECD Guidelines have to be usually applied 
for a safe and consistent risk assessment, even when the chemical’s hazard is not related to 
the tested target system. In this way, some of the most relevant tests are 
reproduction/developmental studies because the endpoints assessed in these protocols and 
the non-observed-adverse-effect levels (NOAELs) obtained are typically taken into account 
not only for reproductive toxicity testing, but also for the risk assessment of general 
systemic effects. For example, the NOAELs of systemic maternal toxicity in the 
teratogenicity study are frequently considered for risk characterization in short-term 
exposure scenarios.  
Guidelines for testing toxicity to reproduction are also highly relevant because the effects of 
chemicals or drugs on germ cells or early embryos may lead to infertility or impaired 
development of pre-implantation embryos, and might result in embryotoxic or teratogenic 
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effects in the progeny (Spielmann, 2005; Krtolica et al., 2009). This is the reason why toxicity 
to reproduction is required in all government regulations for the authorization and 
regulation of most chemicals. For example, extensive screening and multi-generation studies 
(including teratogenicity, fertility and development) are required for registering 
agrochemicals. 
1.2 Necessity of cellular assays in toxicology 
It is obvious that the application of an in vivo test is very expensive, time-consuming and 
involves lots of ethical concerns relating to the use of animals for experimentation purposes. 
Nevertheless, we now go on to illustrate these concerns with some figures. Höfer and 
coworkers (2004) estimated the number of animals needed to apply each in vivo test. It can 
be easily concluded that the number of animals needed to test a single chemical with all the 
above-mentioned available tests is around 4,710. Fleischer (2007) also estimated that the cost 
of this set of tests would be around € 1,800,000.  
Apart from this, the relevance of many in vivo toxicological assays is questionable as regards 
human health because there are times when the animal model is not representative because 
of inter-species differences in pharmacokinetics and toxicokinetics (Wobus and Löser, 2011). 
Such inter-species differences have been detected, for example, in the cases of 13-cis retinoic 
acid (Hendrickx, 1998) and thalidomide (Nau, 1993; Tzimas et al., 1994). Specifically, the 
dramatic consequences of the teratogenic effects of thalidomide on humans urgently lead to 
the need for new, optimized human-specific test systems. 
Therefore due to the aforementioned economical, logistical and ethical concerns, it is 
obvious that the availability of fast, safe, reliable and high throughput alternatives to animal 
experimentation methods would be extremely welcomed by industry, researchers and 
regulatory bodies. Cellular methods fit all these requirements and, due to the availability of 
cellular cultures for all tissues, these methods are good candidates to be employed for 
testing toxicity in all the possible target organ systems (liver, skin, heart, reproduction, etc.).   
1.3 Roles of stem cells in toxicological studies 
Stem cells may play several relevant roles in cellular assays for testing toxicity, and these 
roles can be played in either embryotoxicity or in organogenesis for testing toxicity in adult 
tissues (Figure 1). Indeed, embryonic stem cells (ESC) or reprogrammed-induced 
pluripotent stem cells (iPSC) can be employed through forced directed differentiation 
protocols as a source of adult human cells cultures (hepatocytes, neurons, and others) that 
would be further used for the in vitro testing of respective target organ toxicity 
(hepatotoxicity, neurotoxicity, etc.). This application is useful because it avoids the sacrifice 
of animals for experimentation purposes, allows the use of human cells which usually have 
a limited availability and avoids the need for the above-mentioned interspecies 
extrapolation. This application of stem cells related with organogenesis will be commented 
and explained in more detail in another section of this chapter. Nonetheless, it is relevant to 
remark that the recent iPSC applications in toxicology and drug research provide new 
alternatives to the standard routine tests performed by industry and offer new chemical 
safety assessment strategies (Laustriat et al., 2010; Trosko and Chang, 2010). 
The other role of stem cells in toxicological studies relates to embryotoxicity. Indeed, the 
testing methods relating to these applications take advantage of ESCs to differentiate in adult 
tissues and help the studies into how these differentiation processes are altered by exposure to 
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the tested chemical (Figure 1). The most important and relevant factor for embryotoxicity 
testing is that ESCs mimic early in vivo embryonic development processes and show tissue-
specific expression profiles (Wobus and Löser, 2011). In combination with three-dimensional 
cultures supported by extracellular matrix proteins, stem cell-based systems can mimic the 
microenvironment of the in vivo niche, which is especially relevant in humans for testing 
embryotoxicity (Trosko and Chang, 2010) and for organogenesis (Miki et al., 2011; Lock and 
Tzanakakis., 2009) and further assay of toxicity on the generated cell cultures. 
Developmental toxicity assays with stem cells occupy a prominent position within the 
available battery of cellular assays since some studies have demonstrated that stem cells can 
be used to understand the processes underlying organogenesis, as shown in the case of the 
heart (Miller et al., 2008). Therefore, the study of the interferences in stem cell differentiation 
caused by chemicals can be used to detect potential developmental toxicants. An additional 
advantage of these models is that genetic molecular approaches enable not only for an 
exhaustive analysis of which genes are affected by each substance, but also for the 
subsequent research into the mechanisms of action underlying the teratogenic or 
embryotoxic effects caused by the assessed chemical (Pamies et al., 2011). 
Details of ESCs-based embryotoxicity testing methods will be provided in the following 
sections of this chapter, but can be divided into four categories (Table 1): the validated 
Embryonic Stem cell Test (EST); variations of the EST using molecular endpoints as 
indicators of altered differentiation; the ACDC method, and human cell-based 
embryotoxicity methods. 
 
Methods References 
EST ESAC, 2002; Glenschow et al., 2000, 
2002 and 2004  
Variations of validated EST with molecular end-
points 
Bremer et al., 2001; Buesen et al., 2009; 
Osman et al., 2010; Romero-Lucena., 
2010; Seiler et al., 2004; Stummann et 
al., 2007; van Dartel et al., 2009; 2010a, 
2010b, 2011a, 2011b 
ACDC Barrier et al., 2010; Jeffay et al., 2010 
Human cell-based embryotoxicity Addler et al., 2008a, 2008b  
Table 1. Embryotoxicity testing methods employing embryonic stem cells 
The cellular methods for testing embryotoxicity deserve special mention because, despite 
the validated in vivo OECD guidelines for testing toxicity to reproduction covering fertility, 
teratogenicity and development, there are no specific guidelines available for exclusively 
testing embryotoxicity (Pamies et al., 2011). Indeed, this is a major gap because a guideline 
for this purpose would allow the detection of developmental toxins in early development 
stages without awaiting teratogenicity. 
There are other well-established alternative methods for testing embryotoxicity with 
endpoints relating to differentiation, such as the frog embryo teratogenesis assay on 
xenopus (Bantle et al., 1990), the chicken embryo toxicity screening test on chicken embryos 
(Jelinek et al., 1985), the micromass assay using mouse embryonic mesenchymal cells (Flint, 
1993; Spielmann, 2005), and the mammalian whole embryo culture assay using mouse 
(Sadler et al., 1982) or rat (Schmidt, 1985; Cockroft and Steele, 1987) embryos. Nevertheless, 
all these methods are not based on stem cells and are not of interest in this book.  
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Fig. 1. Role of stem cells in toxicity testing. 
1.4 Earlier toxicity assays with stem cells 
Some of the earliest attempts for testing cytotoxicity, embryotoxicity or teratogenicity 
screening using mammalian cells date back to between two and three decades (Kimmel et 
al., 1982; Schwetz et al., 1991). The most important drawback of all these assays is that they 
rely on somatic cells, which do not entirely reflect the reaction of embryonic cells to toxic 
compounds (Wobus and Löser, 2011). 
Embryotoxicity tests include the analysis of the toxic effects of chemicals on embryonic cells 
in differentiation, whereas cytotoxicity assays measure the chemical-induced alterations of 
metabolic pathways or the structural integrity of cells, which may or may not be directly 
related to cell differentiation (Wobus and Löser, 2011). Both cytotoxicity and embryotoxicity 
assays have been applied with pluripotent stem cells. The determination of cytotoxic effects 
of chemicals based on the colorimetric MTT test for cellular growth and survival (Mosmann, 
1983) was performed with murine ESCs (Laschinski et al., 1991), showing greater sensitivity 
to selected embryotoxic agents than mouse adult cells (fibroblasts). 
In order to overcome the limitations of cytotoxicity assays to determine embryotoxic effects, 
the ESC-derived embryoid body (EB) model was introduced (Wobus et al., 1988; Wobus et 
al., 1991). The ESCs differentiated in EBs for 5-7 days develop in vitro into the progenitor 
cells of all three primary lineages of ectoderm, mesoderm and endoderm (Wobus and 
Boheler, 2005). The fundamentals of the EB model were that early developmental processes 
simulated by EB differentiation would be affected by exposure to toxic chemicals and, 
consequently, specific differentiation processes would be inhibited or accelerated. 
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One of the first experiences to illustrate how embryonic cells could be used for testing 
embryotoxicity was the case of retinoic acid. There is evidence that retinoic acid in vivo acts 
as morphogen by forming a concentration-dependent gradient along embryonic axes, thus 
affecting the antero-posterior patterning of the body axis and limbs (Kessel and Gruss, 
1991). High concentrations of retinoic acid applied to mouse ESCs during early EB 
differentiation (days 0-2) revealed increased neural-specific transcript levels and 
significantly induced neuronal differentiation (Fraichard et al., 1995; Strubing et al., 1995), 
whereas retinoic acid application at lower concentrations applied between days 2 and 5 
induced mesodermal, specifically skeletal muscle and partially cardiac differentiation 
(Wobus et al., 1994). This is in line with the developmental processes in the EB where the 
maximum expression levels of neural plate morphogenesis genes like brachyury and the 
expression of genes associated with dorsal mesoderm specification were observed at around 
day 3 of EB formation (Wobus et al., 1994; Dani et al., 1997). Cardiac and vascular smooth 
muscle cells both originated (at least partially) from the lateral plate mesoderm, and were 
induced by retinoic acid when applied on days 5-7 and 7-11, respectively (Drab et al., 1997). 
Obviously, the specific temporal response of the different cell types within the EB to retinoic 
acid correlated with the retinoic acid receptor gene expression (Rohwedel et al., 1999). These 
early studies provided the basis to subsequently establish the so-called EST method. 
2. The embryonic stem cell method test (EST) 
In the past, several groups have used murine ESC to establish an in vitro embryotoxicity 
assay. Laschinsky et al. (1991) compared cytotoxicity in both ESC and mouse fibroblasts to 
assess the embryotoxic potential of teratogenic agents. The data showed that ESC were more 
sensitive to toxic agents than adult cells. Newall and Beedles (1994) measured both the 
cytotoxicity and the colony-forming potential of ESC after 7 days of culture in the presence 
of teratogenic agents. In these assays, only a few embryotoxic agents could be correctly 
classified. This was probably due to the fact that only two endpoints were selected for the 
biostatistical assessment in the ESC assays, which seems insufficient. To overcome the 
limitations of the previously mentioned ESC tests, a third endpoint value, alterations in cell 
differentiation, was introduced and linked to the two former ones (cytotoxicity in embryonic 
and adult cells). These three endpoints allow the test compounds to be classified into three 
in vivo embryotoxicity categories. 
2.1 Basis of the method 
The fundamentals for the test are that the in vitro tests of basal cytotoxicity are sufficiently 
predictive for the rodent in vivo LD50 assay (Ekwall, 1999; Spielmann et al., 1999) and that 
ESCs show alterations in their in vitro differentiation pattern when exposed to embryotoxic 
chemicals during EB differentiation (Wobus et al., 1994). The EST method is based on the 
potential of D3 mouse ESC to differentiate into beating cardiomyocytes and in determining 
how this differentiation is altered by exposure to chemicals, together with the cytotoxic 
insults in these cells and in a mouse adult cells model. 
Two permanent mouse cell lines are used: D3 embryonic stem cells to represent embryonic 
tissue and 3T3 fibroblasts to represent adult tissue. The test was developed when D3 mouse 
ESC were discovered to be able to form EBs in the absence of the cytokine leukemia 
inhibiting factor which, after 10 days of culture, spontaneously differentiated into 
cardiomyocytes.  
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The basis of the EST protocol is summarized in Figure 2. The test comprised the 
morphological analysis of beating clusters in differentiating EBs (seeded in single wells of 
multiwell plates) and the determination of those concentrations of the test substance at 
which cardiac differentiation was inhibited by 50% after 10 days of exposure (ID50). The 
cytotoxic effects on D3 and 3T3 cells were estimated by determining those concentrations of 
the test substance at which proliferation was inhibited by 50% after 10 days of exposure, 
yielding IC50 D3 and IC50 3T3, respectively. On the basis of these 3 endpoints, a biostatistical 
prediction model formed by three different functions helped assign the tested chemical to 
one embryotoxicity category (strong, weak or non embryotoxic) (Genschow et al., 2000; 
Genschow et al., 2002; Spielmann et al., 2001) (Figure 1). This method is currently validated 
by the European Centre for Validation of Alternative Methods (ECVAM) as a screening 
assay for potentially embryotoxic chemicals (ESAC, 2002).  
2.2 EST performance  
The testing of the 20 test chemicals employed in the EST validation study provided 78% 
accuracy (correct classifications related to the in vivo data) (Genschow et al., 2004). The 
highest precisions were detected for weak and strong embryotoxic chemicals, which were 
correctly detected in 83% and 81% of cases, respectively (Genschow et al., 2000). The poorest 
precision was recorded for the detection of non embryotoxic compounds (70%). Finally, the 
predictability for strongly embryotoxic chemicals was 100%, while that for non- and weakly 
embryotoxic compounds was similar (70 and 72%, respectively), which is considered 
sufficiently high. 
2.3 Limitations of EST 
EST has several limitations. Since D3 mouse ESCs are differentiated as EBs in ‘‘hanging 
drops’’, this test is laborious and time-consuming. EST does not consider molecular 
endpoints to detect cardiac differentiation (formation of beating cardiomyocytes) (Schmidt 
et al., 2001; Piersma, 2004), and it is an assessment based exclusively on histological 
considerations which introduces a high degree of variability. The inclusion of differentiation 
markers of the ectoderm, mesoderm and endoderm lineages and the analysis of the tissue-
specific gene expression have been recommended as additional endpoints for the purpose of 
improving EST’s predictability on the basis of better differentiation assessment. 
As with most in vitro methods, the EST is limited by lack of metabolic competence. This lack 
has been recognized as another potential factor to affect the EST’s experimental outcome 
and the correct classification of tested substances (Verwei et al., 2006). Experiments which 
attempted to add the S9 mix, the mix usually applied as a source of exogenous metabolic 
activation enzymes, failed because it is toxic for D3 mouse ESC. Therefore, the consortium of 
the ReProTect project (Integrated Project of the European Union funded within the 6th 
Framework Programme, including 35 partners focused on alternatives to animal tests for 
reproductive toxicity with the scope of pre-validating and validating the brightest ones) 
recommended other test systems to analyze the potential toxicity of those compounds that 
require metabolic activation (Marx-Stoelting et al., 2009). Other relevant limitation of the 
EST is that this is also incapable of detecting teratogenic chemicals with mechanisms acting 
beyond the initial embryo differentiation steps.  
This method needs an intermediate level of technical difficulty because it requires two 
endpoints and the cultures of two different cell lines. In addition, it does not yield 
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information about the morphological alterations caused by the teratogen as other methods 
do (e.g., whole embryo culture) (Pamies et al., 2011). 
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Fig. 2. Embryonic Stem cell test (EST) method. 
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3. Proposed variations of the EST based on molecular endpoints 
As stated in the previous section, the EST has several limitations, one of which is the most 
relevant: lack of molecular endpoints for a reliable assessment of the degree of 
differentiation achieved by EBs. Indeed, ECVAM has recommended the inclusion of 
molecular endpoints in the EST with a view to improving its performance (Spielman et al., 
2006). A great deal of work has been done to follow this recommendation in an attempt to 
introduce gene expression as biomarkers of differentiation. A second line of work has also 
been introduced, that of reducing the technical complexity of the EST using a single cell 
line.  
3.1 Use of biomarkers of differentiations as endpoints 
Previous studies about lineage-dependent effects of retinoic acid on ESC differentiation 
(Wobus et al., 1994) and the application of reporter gene constructs controlled by cardiac-
specific promoters (Kolossov et al., 1998) have demonstrated that an ESC differentiation 
model is suitable to be analyzed at a cellular level. Genes coding for tissue-specific proteins 
are expressed in the course of ESC differentiation in a pattern which closely resembles the 
time pattern observed during mouse embryogenesis (Rohwedel et al., 2001). For example, 
cardiac-specific transcription factor Nkx2.5, expressed in cardiac precursor cells during 
embryogenesis in vivo, is the first cardiac-specific gene expressed during EB development in 
parallel to the ┙1 subunit of the L-type Ca2+ channel (Fässler et al., 1996), followed by the 
expression of ┙- and ┚-myosin heavy chain isoforms. 
The recent progress made in improving the EST has underlined previous demands to 
implement new embryotoxicity testing strategies using ESCs by analyzing tissue-specific 
genes via the reporter gene expression, automated high-throughput screening for changes in 
gene and protein expression patterns using microchip arrays for transcriptome and 
proteome analyses, and the application of human ESCs (Rohwedel et al., 2001). 
Reporter gene assays for developmental toxicity, specifically for cardiac toxicity (Bremer et 
al., 2001), have been included in the EST. Cardiac markers ┙-myosin heavy chain and ┙-actin 
(both quantified by fluorescence-activated cell sorting (FACS)) have been successfully 
employed instead of the microscopic observation of beating EBs to determine cardiac 
differentiation after exposing D3 EBs to model embryotoxic test substances (Seiler et al., 
2004; Seiler et al., 2006). The FACS-based EST has been successfully adopted for assessing 
developmental toxicity (Buesen et al., 2009). While the molecular FACS-EST shows the same 
sensitivity as the validated EST for the classification of chemicals, test duration is reduced 
and almost identical ID50 values were obtained for ten representative compounds of the 
three classes, indicating that FACS analyses values can serve as a new EST toxicological 
endpoint.  
Other potential biomarker genes of embryotoxicity that may be used in early development 
stages are Pnpla6, α-fetoprotein, nestin and Vgfa. All these genes displayed statistically 
significant reductions in their respective expressions after 5 days of exposure to a non 
cytotoxic dose of 50 ng/ml of embryotoxic 5-fluorouracil (Table 2) (Romero, 2010). These 
marker genes also offer an advantage over the conventional EST method as they are 
recordable after 5 days of exposure instead of the 10 days of differentiation needed for 
obtaining a beating cardiomyocytes. Alpha-fetoprotein has also been independently 
reported as a very sensitive biomarker of exposure to 5-fluorouracil (Pamies et al., 2010). 
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Gene % 
Pnpla6 80±4 
AFP 26±7 
Nes 54±11 
Vgfa 46±17 
Table 2. Expression of several marker genes after 5 days exposure of D3 mouse embryonic 
stem cells in differentiation to 50 ng/ml embryotoxic 5-fluorouracil. The gene expression 
was indicated as a percentage as regards a differentiated control under the same 
conditions, but in the absence of 5-fluorouracil. In all cases, differences in expression as 
regards the control were statistically significant for at least p<0.05. (Data taken from 
Romero, 2010). 
Inclusion of additional differentiation endpoints, specifically of the neural lineage, has been 
requested by researchers and authorities (Spielmann et al., 2006). The purpose of using such 
systems is to correctly classify the substances that were not identified as embryotoxic in the 
conventional EST. Inclusion of parameters for neuronal differentiation into the EST would 
allow, for example, classification in accordance with the in vivo data of methylmercury as a 
highly embryotoxic, whereas the conventional EST failed to correctly classify this compound 
(Stummann et al., 2007). In order to increase the number of molecular markers as endpoints 
of embryotoxicity testing, real-time Taqman RT-PCR analyses have been adopted for the 
EST in pilot studies (zur Nieden et al., 2004). 
Peters and co-workers determined the relative embryotoxic potential by using a modified 
EST screening system (Peters et al., 2008). In this study, 12 compounds were investigated in 
a modified EST performed in 96-well plates. Test substances were applied on day 3 of 
culture for 10 days, and the assay did not involve the preparation of EBs. This newly revised 
high throughput EST allowed the analysis of a larger number of substances, less manual 
work, yet it yielded data comparable to those obtained with the conventional EST. 
Present efforts to improve the EST now address the application of additional lineage-specific 
markers to define additional toxicological endpoints. Other than cardiac markers, markers 
of neuronal, bone and cartilage development are included. However, this will prolong the 
test duration from 7-10 to 30, or even 32 days (Marx-Stoelting et al., 2009). In the future, 
novel molecular endpoints and reporter-based systems will have to be included in the EST 
(Rohwedel et al., 2001; Marx-Stoelting et al., 2009; Spielmann, 2009). Such improvements 
will also be required to establish EST-like tests with human ESCs. 
3.2 Use of transcriptomics and proteomics as endpoints 
The identification of embryotoxic compounds on the basis of analyzing the alterations they 
cause in the expression of genes and proteins relating to the differentiation of embryonic 
stem cells has been proved possible (van Dartel et al., 2009; 2010a; 2010b; 2011a; 2011b; and 
Oshman et al., 2010). By following this methodology in a procedure that includes a 4-day 
assay (three days for embryonic body formation and one additional day to expose cells to 
the assessed chemical), the set of genes called "van_Dartel_heartdiff_24h" was able to 
correctly predict the embryotoxicity of 83% of the assessed chemicals (ten correct predictions 
of a total of 12 assessed chemicals, where two non embryotoxic chemicals were wrongly 
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classified as embryotoxic) (van Dartel et al., 2011a). In the same study, the group of genes 
called "EST biomarker genes" correctly predicted the embryotoxicity of eight of the 12 
assessed chemicals (67%). Here the mistakes corresponded to one non embryotoxic and 
three embryotoxic chemicals, respectively (van Dartel et al., 2011a). 
Protein markers can also be used to detect exposure to embryotoxic chemicals. Osman and 
coworkers found that the embryonic bodies formed from day 3 of differentiation of D3 cells, 
which were further exposed to embryotoxic monobutyl phthalate for 24 hours, expressed 33 
proteins in a differential way, including cardiomyocytes biomarkers (whose expression was 
repressed if compared with controls) and chromatin modulator enzymes (Osman et al., 
2010).  
3.3 The ACDC method 
The Adherent Cell Differentiation and Cytotoxicity (ACDC) assay is a test to establish a 
model system to assess the chemical effect using a single cell culture (instead of two as the 
EST does) in order to improve feasibilities for throughput assays (Barrier et al., 2010). The 
ACDC assay uses quantitative markers for both the differentiation degree and cell 
proliferation. In this assay, pluripotent J1 mouse ESCs are plated in a 96-multiwell plate and 
further cultured in differentiation medium for 9 days. Afterward, each well is assessed for 
the cell number and differentiation to cardiomyocytes (using quantitative in-cell Western 
analysis for myosin heavy chain protein normalized with the cell number). This method has 
already proved suitable for testing the effects of haloacetic acids and their major metabolites 
(Jeffay et al., 2010), but has still not been validated. 
4. Human stem cells for screening cytotoxicity and embryotoxicity 
Development of human ESC-based in vitro systems for testing the embryotoxicity of 
chemicals implies significant progress. The use of human ESCs in in vitro methods would 
enhance their predictability and avoid problems associated with the interpretation of the 
results obtained with animal-based assays in a human context (Wobus and Löser, 2011). For 
example, species-specific differences between mouse and human pre-implantation 
development, as in DNA methylation, DNA repair and the expression of those genes 
involved in drug metabolism, may interfere with the correct interpretation of animal studies 
regarding their significance to humans (Krtolica et al., 2009). The use of human ESC-based 
test systems could avoid the incorrect classification of chemicals due to inter-species 
variations and would, consequently, improve consumers’ safety. 
Adler and co-workers (2008a) provided proofs that human ESCs are a relevant in vitro 
model for developmental toxicity testing. They studied the cytotoxic effects of well-known 
embryotoxicants on human ESC, human ESC-derived progenitors and human foreskin 
fibroblasts. As observed in the respective murine cells, all-trans retinoic acid and 13-cis 
retinoic acid had a stronger cytotoxic effect on pluripotent stem cells than on fibroblasts, 
while the mesenchymal progenitors deriving from human ESC displayed the strongest 
sensitivity to both compounds. While all-trans retinoic acid and 13-cis retinoic acid 
substances revealed comparable cytotoxic effects on human ESC in this study, only all-trans 
retinoic acid was seen to be cytotoxic in mouse ESC in previous analyses. This suggests the 
necessity of developing human ESC-based assays to assess human-specific developmental 
toxicity.  
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In a second study, Adler and co-workers arranged the test system according to the EST, but 
used human instead of mouse ESC (Adler et al., 2008b). The cytotoxic effects of the two well-
known developmental toxicants, 5-fluorouracil and all-trans retinoic acid, on human ESCs 
and human fibroblasts were similar to those previously observed in mice systems. However, 
testing for the potential cytotoxic effects on pluripotent stem cells does not suffice to detect 
the developmental toxicity of chemicals that affect developmental processes (Rohwedel et 
al., 2001). These authors proposed markers of undifferentiated cells such as Oct4, hTert and 
Dusp6, as well as markers of neural plate morphogenesis and early cardiogenesis, such as 
Brachyury and GATA-4 for monitoring cardiac differentiation, thus demonstrating that these 
markers may have the potential to serve as endpoints for developmental toxicity studies 
using a humanized EST (Adler et al., 2008b). 
Despite the progress made, numerous problems have to be solved before human ESC-based 
assays can be implemented into routine procedures for the developmental toxicity testing of 
drugs and chemicals. These problems include the establishment of reliable and reproducible 
differentiation procedures that can be performed in a high-throughput format. The 
predictability, the sensitivity and specificity of the respective test systems for a wider panel 
of chemicals are still to be shown. In addition, very few substances have been tested in the 
different approaches. Furthermore, human ESC-based systems may have the capacity to 
predict human-specific embryotoxic effects which cannot be measured with mouse cell 
systems due to species-specific differences. However, the superiority of human ESC-based 
systems over existing animal in vitro tests for developmental toxicity has still to be shown 
and, in this context, the use of different human ESC lines would prove advantageous. 
5. Induced pluripotent stem cells in toxicological studies 
iPSC play a prominent role in their use as a tool in toxicity tests in the embryotoxicity field 
or as a source of cellular tissues for testing toxicity in adult tissues (Figure 1). These two 
applications are particularly interesting when used with human cells because they will 
eliminate uncertainties deriving from the necessary inter-species interpolation when animal 
cells are used. 
5.1 Applications in embryotoxicity studies 
The successful reprogramming of adult somatic cells into a ESC-like state through genetic 
manipulation (Yu et al., 2007; Takahashi et al., 2007) offers a new opportunity for toxicology 
assay development as reprogrammed somatic cells possess very similar characteristics to 
those of human ESC. Nevertheless, some questions arise as to the use of iPSC for 
toxicological assays. One is whether the different epigenetics of reprogrammed iPSC (Surani 
et al., 2008; Han and Sidhu, 2008) might influence responses to a toxic insult. The other 
challenge is that the derivation of iPSC involves permanent genetic modifications to somatic 
cells due to the use of the viral transduction of recombinant DNA (Yu et al., 2007; Takahashi 
et al., 2007). Integration of recombinant DNA into the genome of iPSC lines might lead these 
cells or their differentiated progenies to behave differently from normal human cells, 
particularly when exposed to toxic challenge. 
The application of human iPSC in embryotoxicity testing might be a promising tool, as well 
as ESC (Heng et al., 2009). However on the basis of the recently reported inconveniences 
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caused by reprogramming, future work has to show whether human iPSC will be applicable 
and offer advantages over human ESC in the developmental toxicology field (Gore et al., 
2011). 
In the future, it is possible that iPSC lines for toxicology screening may also be derived from 
reprogramming primary explanted hepatocytes and cardiomyocytes because such somatic 
lineages have wide-ranging applications in both toxicology and pharmacology screenings 
(Heng et al., 2009). 
5.2 Applications in organogenesis and target organ toxicity testing 
The ability to generate iPSC from somatic cells by the forced expression of reprogramming 
factors Oct3/4 and Sox2, along with either Klf4 or Nanog and Lin28, raises the possibility of 
generating patient-specific cell types of all lineages. Differentiated cell types produced from 
patient’s iPS cells have many potential therapeutic applications, including their use in tissue 
replacement and gene therapy (Si-Tayeb et al., 2010). They also provide a platform for drug 
toxicity screenings. Generation of hepatocytes from iPSC is a particularly appealing goal 
because this parenchymal cell of the liver is associated with several congenital diseases 
(Burlina, 2004) and is the main site of xenobiotic control. 
Mouse iPSC were generated from fibroblasts (Si-Tayeb et al., 2010), and embryos were then 
produced from this iPSC tetraploid complementation using transgenic mice which 
ubiquitously express enhanced green fluorescent protein (EGFP). When embryos were 
generated from mouse iPSC, from which EGFP is absent, all the embryos, including their 
livers, lacked the EGFP expression except in extra embryonic tissues. A thorough 
examination of iPSC-derived embryos and their livers revealed that they appeared to be 
identical to controls. These livers were examined, and the expression of those proteins that 
are characteristic of specific cell types was identified to reveal that, like the control fetal 
livers, the iPSC-derived livers contained hepatocytes (HNF4a positive), endothelial cells 
(GATA4 positive), sinusoidal cells (LYVE1 positive) and Kuppfer cells/macrophage (F4/80 
positive). 
In the cardiogenesis field, the latest studies have revealed that mouse iPSC can differentiate 
into cardiomyocytes by EBs formation or through the use of collagen IV-coated dishes and 
feeder cells (Narazaki et al., 2008; Mauritz et al., 2008). However, it is unknown whether 
iPSC can differentiate into cardiomyocytes without EBs formation and without using 
collagen IV-coated dishes or feeder cells. In addition, myocardial cell differentiation 
efficiency has still not been determined as being uniform or diverse in different iPS cell lines 
(Kaichi et al., 2010). 
The transcription factors, such as GATA4 and Nkx2.5, expressed in the lateral mesoderm 
play important roles in the following heart developmental processes (Molkentin et al., 1997; 
Kasahara et al., 1998). The activities of cardiac transcription factors are regulated, in part, by 
histone acetyltransferases and histone deacetylases (HDACs). In the treatment of ES cells 
with trichostatin A (TSA), a specific HDAC inhibitor has been reported which not only 
induces the acetylation of both GATA4 and histones, but facilitates their differentiation into 
cardiomyocytes (Kawamura et al., 2005). 
In the very near future, it is expected that other cellular types other than hepatocytes and 
cardiocytes can be successfully obtained, as shown in Figure 1. These cell cultures would 
also be suitable for use in toxicity studies as platforms for testing in vitro toxicity on adult 
cells. 
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6. Conclusions and final remarks 
Stem cells are an excellent platform for testing embryotoxicity in vitro on the basis of these 
cells’ capacity to mimic the embryo formation process. Nevertheless, much effort and hard 
work is still needed to find good suitable endpoints for monitoring different differentiation 
stages. There is also the urgent need to go ahead with the characterization of those models 
employing human cells, either ESC or those from reprogrammed iPSC. 
Stem cells also represent a good opportunity to generate adult tissues to test toxicity in such 
tissues,  which again is especially relevant in humans. Nevertheless, the development of 
good differentiation protocols to allow the generation of a variety of cell types apart from 
hepatocytes and cardiocytes is still needed.  
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